Stargardt Disease News and Research

RSS
Stargardt disease, also known as Stargardt macular dystrophy or juvenile macular degeneration, is a condition that involves the retina of the eye. The retina is the layer of the eye which is responsible for sensing light. Most people with Stargardt disease have some loss of vision at a young age, either as a child or an adolescent, although some people may retain good vision until adulthood. It is estimated that about 1 in 10,000 people has Stargardt disease.

Further Reading

Modified vitamin A drug may help prevent age-related macular degeneration

Modified vitamin A drug may help prevent age-related macular degeneration

ARVO announces 2011 award recipients in retinal research

ARVO announces 2011 award recipients in retinal research

ACT seeks European MHRA clearance to initiate hESC derived RPE cell Phase 1/2 study in SMD

ACT seeks European MHRA clearance to initiate hESC derived RPE cell Phase 1/2 study in SMD

Advanced Cell Technology reduces 2010 debt to less than $1 million

Advanced Cell Technology reduces 2010 debt to less than $1 million

ACT's hESC-derived RPE cells receive EMA positive opinion for Orphan Drug Designation for Stargardt's disease

ACT's hESC-derived RPE cells receive EMA positive opinion for Orphan Drug Designation for Stargardt's disease

Alkeus and Columbia University enter license agreement for potential therapies for dry-AMD, Stargardt disease

Alkeus and Columbia University enter license agreement for potential therapies for dry-AMD, Stargardt disease

FDA clears ACT's IND to treat AMD using hESC derived RPE cells

FDA clears ACT's IND to treat AMD using hESC derived RPE cells

NEI awards Case Western Reserve $10M for study of retinal diseases

NEI awards Case Western Reserve $10M for study of retinal diseases

ACT, Roslin Cells collaborate to establish hESC line bank using single-ceblastomere technique

ACT, Roslin Cells collaborate to establish hESC line bank using single-ceblastomere technique

ACT files IND application to initiate Phase I/II study for Dry AMD

ACT files IND application to initiate Phase I/II study for Dry AMD

FDA grants ACT clearance for Phase I/II clinical trial of hESC derived retinal cells in patients with SMD

FDA grants ACT clearance for Phase I/II clinical trial of hESC derived retinal cells in patients with SMD

ACT receives patent for RPE cells to treat retinal degeneration

ACT receives patent for RPE cells to treat retinal degeneration

ACT comments on federal fund blocking for embryonic stem cell research

ACT comments on federal fund blocking for embryonic stem cell research

Scientific paper explains impact of visual cycle modulation in neurovascular retinopathy

Scientific paper explains impact of visual cycle modulation in neurovascular retinopathy

ACT awarded patent for production processes of RPE cells from hESCs

ACT awarded patent for production processes of RPE cells from hESCs

Retinitis Pigmentosa: Embryonic stem cells for replacement of diseased retinal cells and restoration of sight

Retinitis Pigmentosa: Embryonic stem cells for replacement of diseased retinal cells and restoration of sight

New vector carries big genes linked to inherited blindness

New vector carries big genes linked to inherited blindness